Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis serogroup W-135. The vaccine... The vaccine contains N. meningitis serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae grown in another culture.
- First approval
- Canada, 2006 · United States, 2005
- Also known as
- Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine
- Brand names
Resolves to
What you can answer from here — as of January 07, 2026
Which other approved drugs treat the same conditions as Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account